IDH2 and glioma: In patients within the astrocytic glioma/glioblastoma, IDH-mutant glioma cluster, median overall survival with WHO grade III/IV versus WHO grade II was 63.0 versus 95.8 months (p = 0.007, Cox proportional hazards regression, Fig. 7c).